Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma
Andreas Rosenwald, George Wright, Karen Leroy, Xin Yu, Philippe Gaulard, Randy D Gascoyne, Wing C Chan, Tong Zhao, Corinne Haioun, Timothy C Greiner, Dennis D Weisenburger, James C Lynch, Julie Vose, James O Armitage, Erlend B Smeland, Stein Kvaloy, Harald Holte, Jan Delabie, Elias Campo, Emili Montserrat, Armando Lopez-Guillermo, German Ott, H Konrad Muller-Hermelink, Joseph M Connors, Rita Braziel, Thomas M Grogan, Richard I Fisher, Thomas P Miller, Michael LeBlanc, Michael Chiorazzi, Hong Zhao, Liming Yang, John Powell, Wyndham H Wilson, Elaine S Jaffe, Richard Simon, Richard D Klausner, Louis M Staudt, Andreas Rosenwald, George Wright, Karen Leroy, Xin Yu, Philippe Gaulard, Randy D Gascoyne, Wing C Chan, Tong Zhao, Corinne Haioun, Timothy C Greiner, Dennis D Weisenburger, James C Lynch, Julie Vose, James O Armitage, Erlend B Smeland, Stein Kvaloy, Harald Holte, Jan Delabie, Elias Campo, Emili Montserrat, Armando Lopez-Guillermo, German Ott, H Konrad Muller-Hermelink, Joseph M Connors, Rita Braziel, Thomas M Grogan, Richard I Fisher, Thomas P Miller, Michael LeBlanc, Michael Chiorazzi, Hong Zhao, Liming Yang, John Powell, Wyndham H Wilson, Elaine S Jaffe, Richard Simon, Richard D Klausner, Louis M Staudt
Abstract
Using current diagnostic criteria, primary mediastinal B cell lymphoma (PMBL) cannot be distinguished from other types of diffuse large B cell lymphoma (DLBCL) reliably. We used gene expression profiling to develop a more precise molecular diagnosis of PMBL. PMBL patients were considerably younger than other DLBCL patients, and their lymphomas frequently involved other thoracic structures but not extrathoracic sites typical of other DLBCLs. PMBL patients had a relatively favorable clinical outcome, with a 5-yr survival rate of 64% compared with 46% for other DLBCL patients. Gene expression profiling strongly supported a relationship between PMBL and Hodgkin lymphoma: over one third of the genes that were more highly expressed in PMBL than in other DLBCLs were also characteristically expressed in Hodgkin lymphoma cells. PDL2, which encodes a regulator of T cell activation, was the gene that best discriminated PMBL from other DLBCLs and was also highly expressed in Hodgkin lymphoma cells. The genomic loci for PDL2 and several neighboring genes were amplified in over half of the PMBLs and in Hodgkin lymphoma cell lines. The molecular diagnosis of PMBL should significantly aid in the development of therapies tailored to this clinically and pathogenetically distinctive subgroup of DLBCL.
Figures
References
- Barth, T.F., F. Leithauser, S. Joos, M. Bentz, and P. Moller. 2002. Mediastinal (thymic) large B-cell lymphoma: where do we stand? Lancet Oncol. 3:229–234.
- Bishop, P.C., W.H. Wilson, D. Pearson, J. Janik, E.S. Jaffe, and P.C. Elwood. 1999. CNS involvement in primary mediastinal large B-cell lymphoma. J. Clin. Oncol. 17:2479–2485.
- Alizadeh, A.A., M.B. Eisen, R.E. Davis, C. Ma, I.S. Lossos, A. Rosenwald, J.C. Boldrick, H. Sabet, T. Tran, X. Yu, et al. 2000. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 403:503–511.
- Rosenwald, A., G. Wright, W.C. Chan, J.M. Connors, E. Campo, R.I. Fisher, R.D. Gascoyne, H.K. Muller-Hermelink, E.B. Smeland, J.M. Giltnane, et al. 2002. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N. Engl. J. Med. 346:1937–1947.
- Wright, G., B. Tan, A. Rosenwald, E.H. Hurt, A. Wiestner, and L.M. Staudt. 2003. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B Cell lymphoma. Proc. Natl. Acad. Sci. USA. In press.
- Joos, S., M.I. Otano-Joos, S. Ziegler, S. Bruderlein, S. du Manoir, M. Bentz, P. Moller, and P. Lichter. 1996. Primary mediastinal (thymic) B-cell lymphoma is characterized by gains of chromosomal material including 9p and amplification of the REL gene. Blood. 87:1571–1578.
- Bentz, M., T.F. Barth, S. Bruderlein, D. Bock, M.J. Schwerer, M. Baudis, S. Joos, A. Viardot, A.C. Feller, H.K. Muller-Hermelink, et al. 2001. Gain of chromosome arm 9p is characteristic of primary mediastinal B-cell lymphoma (MBL): comprehensive molecular cytogenetic analysis and presentation of a novel MBL cell line. Genes Chromosomes Cancer. 30:393–401.
- Joos, S., M. Kupper, S. Ohl, F. von Bonin, G. Mechtersheimer, M. Bentz, P. Marynen, P. Moller, M. Pfreundschuh, L. Trumper, and P. Lichter. 2000. Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells. Cancer Res. 60:549–552.
- Zarate-Osorno, A., L.J. Medeiros, D.L. Longo, and E.S. Jaffe. 1992. Non-Hodgkin's lymphomas arising in patients successfully treated for Hodgkin's disease. A clinical, histologic, and immunophenotypic study of 14 cases. Am. J. Surg. Pathol. 16:885–895.
- Gonzalez, C.L., L.J. Medeiros, and E.S. Jaffe. 1991. Composite lymphoma. A clinicopathologic analysis of nine patients with Hodgkin's disease and B-cell non-Hodgkin's lymphoma. Am. J. Clin. Pathol. 96:81–89.
- Jaffe, E.S., and K. Muller-Hermelink. 1999. Relationship between Hodgkin's disease and non-Hodgkin's lymphomas. Hodgkin's Disease. P.M. Mauch, J.O. Armitage, V. Diehl, R.T. Hoppe, and L.M. Weiss, editors. Lippincott Williams & Wilkens, Philadelphia, PA. 181–191.
- Haioun, C., P. Gaulard, F. Roudot-Thoraval, M. Divine, H. Jouault, J.P. Lebourgeois, M. Kuentz, J.P. Farcet, and F. Reyes. 1989. Mediastinal diffuse large-cell lymphoma with sclerosis: a condition with a poor prognosis. Am. J. Clin. Oncol. 12:425–429.
- Lavabre-Bertrand, T., D. Donadio, N. Fegueux, D. Jessueld, J. Taib, D. Charlier, T. Rousset, J.M. Emberger, P. Baldet, and M. Navarro. 1992. A study of 15 cases of primary mediastinal lymphoma of B-cell type. Cancer. 69:2561–2566.
- Abou-Elella, A.A., D.D. Weisenburger, J.M. Vose, J.P. Kollath, J.C. Lynch, M.A. Bast, P.J. Bierman, T.C. Greiner, W.C. Chan, and J.O. Armitage. 1999. Primary mediastinal large B-cell lymphoma: a clinicopathologic study of 43 patients from the Nebraska Lymphoma Study Group. J. Clin. Oncol. 17:784–790.
- Zinzani, P.L., M. Martelli, M. Magagnoli, E. Pescarmona, L. Scaramucci, F. Palombi, M. Bendandi, M.P. Martelli, S. Ascani, G.F. Orcioni, et al. 1999. Treatment and clinical management of primary mediastinal large B-cell lymphoma with sclerosis: MACOP-B regimen and mediastinal radiotherapy monitored by (67)Gallium scan in 50 patients. Blood. 94:3289–3293.
- Copie-Bergman, C., A. Plonquet, M.A. Alonso, M.L. Boulland, J. Marquet, M. Divine, P. Moller, K. Leroy, and P. Gaulard. 2002. MAL expression in lymphoid cells: further evidence for MAL as a distinct molecular marker of primary mediastinal large B-cell lymphomas. Mod. Pathol. 15:1172–1180.
- Copie-Bergman, C., M.L. Boulland, C. Dehoulle, P. Moller, J.P. Farcet, M.J. Dyer, C. Haioun, P.H. Romeo, P. Gaulard, and K. Leroy. 2003. Interleukin 4-induced gene 1 is activated in primary mediastinal large B-cell lymphoma. Blood. 101:2756–2761.
- Rosenwald, A., G. Wright, A. Wiestner, W.C. Chan, J.M. Connors, E. Campo, R.D. Gascoyne, T.M. Grogan, H.K. Muller-Hermelink, E.B. Smeland, et al. 2003. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell. 3:185–197.
- Eisen, M.B., P.T. Spellman, P.O. Brown, and D. Botstein. 1998. Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. USA. 95:14863–14868.
- Anagnostopoulos, I., F. Dallenbach, and H. Stein. 2001. Diffuse large cell lymphomas. Neoplastic Hematopathology. D.M. Knowles, editor. Lippincott Williams & Wilkins, Philadelphia, PA. 855–905.
- Wright, G., B. Tan, A. Rosenwald, E.H. Hurt, A. Wiestner, and L.M. Staudt. 2003. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc. Natl. Acad. Sci. USA. 100:9991–9996.
- Stein, H., J. Gerdes, U. Schwab, H. Lemke, V. Diehl, D.Y. Mason, H. Bartels, and A. Ziegler. 1983. Evidence for the detection of the normal counterpart of Hodgkin and Sternberg-Reed cells. Hematol. Oncol. 1:21–29.
- Peh, S.C., L.H. Kim, and S. Poppema. 2001. TARC, a CC chemokine, is frequently expressed in classic Hodgkin's lymphoma but not in NLP Hodgkin's lymphoma, T-cell-rich B-cell lymphoma, and most cases of anaplastic large cell lymphoma. Am. J. Surg. Pathol. 25:925–929.
- Kuppers, R., U. Klein, I. Schwering, V. Distler, A. Brauninger, G. Cattoretti, Y. Tu, G.A. Stolovitzky, A. Califano, M.L. Hansmann, and R. Dalla-Favera. 2003. Identification of Hodgkin and Reed-Sternberg cell-specific genes by gene expression profiling. J. Clin. Invest. 111:529–537.
- Nacheva, E., M.J. Dyer, C. Metivier, D. Jadayel, G. Stranks, R. Morilla, J.M. Heward, T. Holloway, S. O'Connor, P.C. Bevan, et al. 1994. B-cell non-Hodgkin's lymphoma cell line (Karpas 1106) with complex translocation involving 18q21.3 but lacking BCL2 rearrangement and expression. Blood. 84:3422–3428.
- Mauch, P.M., L.A. Kalish, M. Kadin, C.N. Coleman, R. Osteen, and S. Hellman. 1993. Patterns of presentation of Hodgkin disease. Implications for etiology and pathogenesis. Cancer. 71:2062–2071.
- Addis, B.J., and P.G. Isaacson. 1986. Large cell lymphoma of the mediastinum: a B-cell tumour of probable thymic origin. Histopathology. 10:379–390.
- Isaacson, P.G., A.J. Norton, and B.J. Addis. 1987. The human thymus contains a novel population of B lymphocytes. Lancet. 2:1488–1491.
- Jaffe, E.S., N.L. Harris, H. Stein, and J.W. Vardiman. 2001. Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon, France. 351 pp.
- Freeman, G.J., A.J. Long, Y. Iwai, K. Bourque, T. Chernova, H. Nishimura, L.J. Fitz, N. Malenkovich, T. Okazaki, M.C. Byrne, et al. 2000. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192:1027–1034.
- Latchman, Y., C.R. Wood, T. Chernova, D. Chaudhary, M. Borde, I. Chernova, Y. Iwai, A.J. Long, J.A. Brown, R. Nunes, et al. 2001. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol. 2:261–268.
- Dong, H., G. Zhu, K. Tamada, and L. Chen. 1999. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat. Med. 5:1365–1369.
- Dong, H., S.E. Strome, D.R. Salomao, H. Tamura, F. Hirano, D.B. Flies, P.C. Roche, J. Lu, G. Zhu, K. Tamada, et al. 2002. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8:793–800.
- Curiel, T.J., S. Wei, H. Dong, X. Alvarez, P. Cheng, P. Mottram, R. Krzysiek, K.L. Knutson, B. Daniel, M.C. Zimmermann, et al. 2003. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat. Med. 9:562–567.
- Liu, X., J.X. Gao, J. Wen, L. Yin, O. Li, T. Zuo, T.F. Gajewski, Y.X. Fu, P. Zheng, and Y. Liu. 2003. B7DC/PDL2 promotes tumor immunity by a PD-1–independent mechanism. J. Exp. Med. 197:1721–1730.
- Dong, H., and L. Chen. 2003. B7-H1 pathway and its role in the evasion of tumor immunity. J. Mol. Med. 81:281–287.
Source: PubMed